Research Articles
Reduced Inter- and Intraindividual Variability in Cyclosporine Pharmacokinetics from a Microemulsion Formulation

https://doi.org/10.1002/jps.2600830336Get rights and content

Abstract

The inter- and intraindividual variability of cyclosporine pharmacokinetics from a microemulsion formulation were compared with the currently marketed formulation In a sequential bioreplication study. Twenty-four healthy male volunteers were randomized to receive each formulation on two separate occasions; the reference treatment was a single oral dose of 300 mg of Sandimmune and the test treatment was a single oral dose of 180 mg of Sandimmune Neoral, both given as soft gelatin capsules. Serial venous blood samples were obtained over a period of 48 h after each administration, and cyclosporine concentrations were measured in whole blood by a specific monoclonal RIA method. Between- and within-subject variabilities were quantified from the appropriate sums of squares from analysis of variance and statistically compared between formulations. Both inter- and intraindividual variation for the peak concentration, time to reach the peak, area under the curve, and terminal half-life of the test formulation were significantly reduced (p < 0.05) with two exceptions. For area under the curve between subjects (p < 0.2) and peak concentration within subjects (p < 0.1), trends toward reduced variability for the test formulation were evident. These results were further reflected in the inter- and intraindividual coefficients of variation of the pharmacokinetic parameters that ranged from 3 to 22% for the test formulation comparedwith 19to41 % for the reference formulation. Incomparison with the currently marketed formulation, reduced variability in the pharmacokinetics of cyclosporine following oral administration of Sandimmune Neoral provides a more predictable and consistent concentration-time profile.

References (11)

  • TrullA.K. et al.

    Lancet

    (1993)
  • PtachinskiR.J. et al.

    Clin. Pharmacokinet.

    (1986)
  • GrevelJ.

    Transplant Proc

    (1986)
  • DreweJ. et al.

    Br. J. Clin. Pharmacol.

    (1992)
  • ReymondJ.P. et al.

    J. Pharmacokinet. Biopharm.

    (1989)
There are more references available in the full text version of this article.

Cited by (313)

  • Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

    2021, Acta Pharmaceutica Sinica B
    Citation Excerpt :

    Cyclosporine A is the one of the most successful oral peptide products in market. The combination of the cyclic lipophilic undecapeptide with SNEDDS technologies enables the oral bioavailability achieve 19%–40%360. Meanwhile, SNEDDS formulation (Neoral®) overcome the high intra- and inter-patients pharmacokinetics variability in a high percentage of patients by better control of droplet size, increasing intestinal permeability and inhibiting P-glycoprotein efflux and P450 metabolism360.

View all citing articles on Scopus
View full text